NPPA has revised ceiling prices of scheduled drug formulations based on a Wholesale Price Index increase of 0.64956%, effective 1 April 2026. Manufacturers must ensure that prices do not exceed the notified ceiling limits and comply with reporting requirements under the Drugs (Prices Control) Order, 2013. This revision aims to regulate drug pricing, ensure affordability, and maintain transparency in the pharmaceutical sector across all scheduled formulations.
The National Pharmaceutical Pricing Authority (NPPA) has issued a notification revising the ceiling prices of scheduled drug formulations based on the annual Wholesale Price Index increase of 0.64956%.
The revised prices will come into effect from 1 April 2026 and apply to various essential medicines listed under the Drugs (Prices Control) Order, 2013. The order mandates that:
- Manufacturers must not sell scheduled formulations above the notified ceiling prices plus applicable taxes.
- Manufacturers may revise prices based on WPI if existing prices are lower than the ceiling.
- Revised pricing details must be submitted to NPPA in Form-II within 15 days.
- Retailers and dealers must display updated price lists prominently.
The notification also requires quarterly reporting of production, import, and sales data, and prior approval for new drugs. Non-compliance may lead to recovery of overcharged amounts with interest. This measure ensures price control, affordability, and regulatory compliance in the pharmaceutical sector. the list of medicines mentioned below:
- Acetyl Salicylic Acid Tablet 300mg,
- Calcium carbonate Tablet 250 mg ,
- Condoms 1 Condom,
- Dapsone Tablet 50 mg ,
- Medroxy Progesterone Acetate Tablet 5mg,
- Rifampicin Tablet 450mg.